OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

Core Viewpoint - OKYO Pharma Limited has announced a public offering of 10,815,000 ordinary shares at a price of $1.85 per share, aiming to raise approximately $20 million before expenses and discounts [1][2]. Group 1: Offering Details - The gross proceeds from the offering are expected to be around $20 million, with the potential to increase to approximately $23 million if the underwriter fully exercises its option to purchase additional shares [2]. - The offering is managed solely by Piper Sandler & Co., and is expected to close around February 17, 2026, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily be used for clinical development of product candidates, general corporate purposes, and working capital [2]. Group 3: Company Overview - OKYO Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, with shares traded on the Nasdaq Capital Market [6]. - The company has recently completed a successful Phase 2 trial of its lead drug, urcosimod, for NCP and plans to initiate a Phase 2b/3 study involving approximately 150 subjects in the first half of the year [6].